Fig 1.
Antibody index (AI) of rubella (RV) and cytomegalovirus (CMV) in all 81 patients.
AI was determined using the Goldmann-Witmer-Desmonts coefficient. The diagnosis for PSS was confirmed by AI > 3.0, ΔE >0.200 for CMV and for FU by AI >3.0, ΔE >0.200 for RV.
Table 1.
Baseline demographics and clinical presentation of all patients.
Table 2.
Summary of cytokine levels (pg/mL) in all measured aqueous humor, using nonparametric Mann-Whitney-Test.
Fig 2.
Increased mediator concentrations of T helper 1 cells for cytomegalovirus positive Posner-Schlossman-Syndrome (PSS) and rubella positive Fuchs´ Uveitis (FU) compared to the control group.
The concentrations (pg/mL) were compared between PSS and FU vs. controls by nonparametric Mann-Whitney-Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig 3.
Mediators’ concentrations for cytomegalovirus positive Posner-Schlossman-Syndrome (PSS) and rubella positive Fuchs´ Uveitis (FU) and control group.
The concentrations (pg/mL) were compared between PSS and FU vs. controls, and PSS vs. FU by nonparametric Mann-Whitney-Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig 4.
Cluster analysis of aqueous cytokine levels in Posner-Schlossman-Syndrome (PSS), Fuchs´Uveitis (FU) patients, and control group.
The measured values of analyzed concentration are represented in heatmaps with colors according to (per-analyte) mean-centered and sigma-normalized data (Z-score) after asinh transformation of the raw values. The height of the dendrogram represents the dissimilarity between clusters of patient samples (columns) according to the profile of secreted immune mediators (rows). The top-bars indicate the PSS (yellow), the FU (cyan) and control group (white), as well as IOP level of each individual (light grey: IOP< = 20, grey: IOP>20, black: IOP>40), topical steroid treatment (white: no treatment), topical anti-glaucoma treatment (white: no, light grey: Brimonidine/Timolol, grey: Dorzolamide/Timolol), and systemic anti-glaucoma treatment with acetazolamide (white: no treatment). A) Simultaneous analysis of data from all three groups indicates that one part of PSS group with high IOP and low levels of mediators fall into a single cluster with a distinct immune mediator expression profile. B) Clustering performed in each group separately shows that within the PSS group patients with mostly low levels of mediators have also high IOP and have been treated with acetazolamide.
Fig 5.
Spearman correlations of median concentrations mediators (pg/mL) with intraocular pressure (IOP) in the Posner-Schlossman-Syndrome (PSS) group.
Immune mediators (IL-b, IL-1RA, IL-4, IL-9, IL-15, IFN-γ, FGFbasic, MCP-1 and MIP-1α) correlate negatively with IOP in the total PSS group (black and light grey). Patients treated with acetazolamide (light grey) show lower immune mediators levels. mmHg = millimeter of mercury.